Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19.
Nicolas HoertelMarina Sánchez-RicoRaphaël VernetAnne-Sophie JannotAntoine NeurazCarlos BlancoCédric LemogneGuillaume AiragnesNicolas ParisChristel DanielAlexandre GramfortGuillaume LemaitreMélodie BernauxAli BellamineNathanaël BeekerFrédéric Limosinnull nullPublished in: Clinical drug investigation (2021)
Our results suggest that chlorpromazine prescribed at a mean daily dose of 70.8 mg (SD 65.3) was not associated with reduced mortality.